ASX-listed oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in developing a robust drug pipeline comprising CAR-T and targeted therapies (PTX-100 & PTX-200) for various…

Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has announced its June 2021 results, marked by impressive progress in its cancer programs and a robust financial…

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage oncology company focussed on driving multiple cancer programs for its…

In an update that endorses the potential benefits of Prescient Therapeutic’s (ASX:PTX) anti-cancer drug PTX-100, the Company stated that the first-in-class compound demonstrated an excellent…

Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an early clinical trial – and seemed to benefit two patients…

Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its PTX-100 drug in a basket trial of patients with solid…

Prescient Therapeutics (PTX) is progressing the trial of its cancer-blocking drug PTX100 following successful results from Phase 1b of the trial. The cancer treatment company…

The US Food and Drug Administration has assigned a fast track designation to a new CAR-T cancer treatment for multiple myeloma patients. The designation comes…

Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing demonstrated the company’s OmniCAR binding systems for next-generation CAR-T therapies…

In an upbeat development, Prescient Therapeutics Limited (ASX:PTX) has announced outstanding findings from in silico immunogenicity testing of OmniCAR’s key binding components – SpyTag and…